Pitcairn Co. Takes $328,000 Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Pitcairn Co. purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,259 shares of the company’s stock, valued at approximately $328,000.

Several other institutional investors also recently bought and sold shares of DNLI. Algert Global LLC raised its stake in shares of Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after buying an additional 21,975 shares in the last quarter. Intech Investment Management LLC purchased a new position in Denali Therapeutics in the third quarter worth $861,000. Quest Partners LLC acquired a new stake in Denali Therapeutics in the third quarter valued at $73,000. Swiss National Bank boosted its position in shares of Denali Therapeutics by 7.7% during the 3rd quarter. Swiss National Bank now owns 250,700 shares of the company’s stock worth $7,303,000 after purchasing an additional 17,900 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in shares of Denali Therapeutics by 6.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 138,862 shares of the company’s stock worth $4,045,000 after purchasing an additional 8,358 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on DNLI. Cantor Fitzgerald downgraded shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Citigroup increased their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, November 7th. JPMorgan Chase & Co. dropped their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Bank of America lifted their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $38.90.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 86,578 shares of company stock valued at $2,474,440. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $24.68 on Wednesday. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33. The firm has a 50 day moving average price of $27.76 and a 200 day moving average price of $24.38. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -8.94 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm earned ($0.72) EPS. Sell-side analysts predict that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.